Sponsor
GlaxoSmithKline
Clinical research sponsor
Clinical trials
60 shownA Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)NCT07780656 · lead sponsor · 2026-09-11
RECRUITINGA Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)NCT07602855 · lead sponsor · 2026-09-09
RECRUITINGA Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]NCT07802704 · lead sponsor · 2026-09-01
RECRUITINGA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)NCT07645248 · lead sponsor · 2026-09-01
RECRUITINGA Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)NCT07780669 · lead sponsor · 2026-08-27
RECRUITINGA Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)NCT07782996 · lead sponsor · 2026-08-27
RECRUITINGA Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)NCT07780643 · lead sponsor · 2026-08-27
RECRUITINGA Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283NCT07712393 · lead sponsor · 2026-07-17
RECRUITINGA Study of Depemokimab in Participants of 6 to 11 Years of AgeNCT07671001 · lead sponsor · 2026-06-25
RECRUITINGA Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandNCT07502560 · lead sponsor · 2026-03-31
RECRUITINGA Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaNCT07456033 · lead sponsor · 2026-03-13
RECRUITINGFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPCNCT07332455 · lead sponsor · 2026-02-10
RECRUITINGA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)NCT07371468 · lead sponsor · 2026-02-10
RECRUITINGA Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsNCT07277270 · lead sponsor · 2025-12-03
RECRUITINGeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339 · lead sponsor · 2025-10-20
RECRUITINGOpen-label Extension Study in Participants With Early Alzheimer's DiseaseNCT07105709 · lead sponsor · 2025-08-14
RECRUITINGA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · lead sponsor · 2025-08-11
RECRUITINGDepemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)NCT06961214 · lead sponsor · 2025-06-23
RECRUITINGDepemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · lead sponsor · 2025-06-20
RECRUITINGA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerNCT06990880 · lead sponsor · 2025-06-12
RECRUITINGA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 InclusiveNCT06433921 · lead sponsor · 2024-08-14
RECRUITINGDepemokimab Asthma Imaging and Bronchoscopy Sub-StudyNCT06979323 · lead sponsor · 2024-07-19
RECRUITINGA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaNCT05757102 · lead sponsor · 2023-04-24
RECRUITINGA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyNCT04641247 · lead sponsor · 2021-04-16
RECRUITINGA Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNCT07862114 · lead sponsor · 2026-10-16
NOT_YET_RECRUITINGEvaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)NCT06405230 · lead sponsor · 2025-10-10
TERMINATEDA Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild AsthmaNCT06702462 · lead sponsor · 2025-03-11
COMPLETEDA Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaNCT06748053 · lead sponsor · 2025-02-10
ACTIVE_NOT_RECRUITINGStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)NCT06497504 · lead sponsor · 2024-09-17
ACTIVE_NOT_RECRUITINGStudy of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy ParticipantsNCT06506266 · lead sponsor · 2024-07-29
COMPLETEDRetrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple IndicationsNCT06488703 · lead sponsor · 2024-07-01
COMPLETEDA Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · lead sponsor · 2024-06-10
ACTIVE_NOT_RECRUITINGA Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 InclusiveNCT06433908 · lead sponsor · 2024-06-04
COMPLETEDA Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaNCT06261957 · lead sponsor · 2024-05-31
COMPLETEDPragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaNCT06372496 · lead sponsor · 2024-04-16
ACTIVE_NOT_RECRUITINGREIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyNCT06041386 · lead sponsor · 2024-03-20
ACTIVE_NOT_RECRUITINGA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseNCT06154837 · lead sponsor · 2023-11-27
ACTIVE_NOT_RECRUITINGEfficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseNCT06079190 · lead sponsor · 2023-10-20
TERMINATEDA Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainNCT05838755 · lead sponsor · 2023-09-20
TERMINATEDA Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT04923347 · lead sponsor · 2023-06-06
COMPLETEDGreen (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy ParticipantsNCT05791565 · lead sponsor · 2023-04-03
COMPLETEDA Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of OtilimabNCT05304130 · lead sponsor · 2023-02-08
WITHDRAWNPhase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05677347 · lead sponsor · 2023-01-23
COMPLETEDA Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult ParticipantsNCT05602025 · lead sponsor · 2022-12-13
COMPLETEDTo Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDNCT05535972 · lead sponsor · 2022-10-14
COMPLETEDA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · lead sponsor · 2022-10-14
ACTIVE_NOT_RECRUITINGEfficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild AsthmaNCT05398198 · lead sponsor · 2022-06-09
COMPLETEDEfficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT05274750 · lead sponsor · 2022-04-22
COMPLETEDEfficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)NCT05281523 · lead sponsor · 2022-04-18
COMPLETEDFirst-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsNCT05277051 · lead sponsor · 2022-03-22
ACTIVE_NOT_RECRUITINGAn Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)NCT05243680 · lead sponsor · 2022-03-01
COMPLETEDPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3NCT06926673 · lead sponsor · 2021-12-23
COMPLETEDStudy of GSK3511294 in Healthy Chinese ParticipantsNCT05140200 · lead sponsor · 2021-12-10
COMPLETEDA Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy ParticipantsNCT05131971 · lead sponsor · 2021-11-01
COMPLETEDA Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionNCT04880031 · lead sponsor · 2021-09-30
COMPLETEDA First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy ParticipantsNCT05044325 · lead sponsor · 2021-09-20
TERMINATEDEfficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaNCT04937387 · lead sponsor · 2021-07-29
COMPLETEDEfficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic AsthmaNCT04276233 · lead sponsor · 2021-06-29
COMPLETEDEfficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseNCT04915755 · lead sponsor · 2021-06-28
ACTIVE_NOT_RECRUITINGMolecular Disease Characterization Initiative (MDCI)NCT04772053 · lead sponsor · 2021-05-25
TERMINATEDSponsor roles
lead sponsor1,082
collaborator497
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.